« Previous Next » The Journal of Pediatrics
Volume 156, Issue 4 , Pages 556-561.e1 , April 2010

Two-Year Neurodevelopmental Outcomes of Ventilated Preterm Infants Treated with Inhaled Nitric Oxide

Michele C. Walsh, MD, MSE
- Case Western Reserve University, Cleveland, OH
- Reprint requests: Michele C. Walsh, MD, MSE, Rainbow Babies & Children's Hospital, Case Medical Center, MS 6010, 11100 Euclid Ave, Cleveland, OH 44106-6010.
Anna Maria Hibbs, MD, MSCE
- Case Western Reserve University, Cleveland, OH
Camilia R. Martin, MD
- Harvard Medical School, Boston, MA
Avital Cnaan, PhD
- National Children's Medical Center, Washington, DC
Roberta L. Keller, MD
- University of California at San Francisco, San Francisco, CA
Eric Vittinghoff, PhD
- University of California at San Francisco, San Francisco, CA
Richard J. Martin, MD
- Case Western Reserve University, Cleveland, OH
William E. Truog, MD
- University of Missouri-Kansas City, Kansas City, MO
Philip L. Ballard, MD, PhD
- University of California at San Francisco, San Francisco, CA
Arlene Zadell, RN
- Case Western Reserve University, Cleveland, OH
Sandra R. Wadlinger, MS, RRT
- The Children's Hospital of Philadelphia, Philadelphia, PA
Christine E. Coburn, MSN
- The Children's Hospital of Philadelphia, Philadelphia, PA
Roberta A. Ballard, MD
- University of California at San Francisco, San Francisco, CA
NO CLD Study Group
- Additional members of the NO CLD Study Group are available at www.jpeds.com (Appendix).

Received 13 July 2009 ,Revised 2 September 2009 ,Accepted 14 October 2009.

To access this article, please choose from the options below

Supported by grants (U01-HL62514, P50-HL56401, P30- HD26979, MRDDRC-P30, and HD26979) from the National Institutes of Health and grants (M01-RR00240, M01-RR00084, M01-RR00425, M01-RR001271, M01-RR00064, and M01-RR00080) from the General Clinical Research Centers Program. Inhaled nitric oxide and the delivery system for the initial trial and support for completion and analysis of follow-up data were provided by INO Therapeutics (now IKARIA). The company was not involved in study design, safety monitoring, data analysis, data interpretation, or manuscript preparation. A.H. was supported by a Career Development award (NICHD K23 HD056299). R.B. received unrestricted grant support for additional biostatistical analyses of the trial from iNO Therapeutics (now IKARIA). M.W. received support from iNO Therapeutics to fund the research nurse coordinator for follow-up of this trial. The authors declare no other conflicts of interest.